Phase I trial of temozolomide using an extended continuous oral schedule
CS Brock, ES Newlands, SR Wedge, M Bower… - Cancer research, 1998 - AACR
Temozolomide, a methylating imidazotetrazinone, has antitumor activity against gliomas,
malignant melanoma, and mycosis fungoides and is presently administered as a 5-day oral …
malignant melanoma, and mycosis fungoides and is presently administered as a 5-day oral …
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients
Difficulties in direct measurement of drug concentrations in human tissues have hampered
the understanding of drug accumulation in tumors and normal tissues. We propose a new …
the understanding of drug accumulation in tumors and normal tissues. We propose a new …
Metabolic Activation of Temozolomide Measured in Vivo Using Positron Emission Tomography
…, S Osman, SK Luthra, ASO Ranicar, CS Brock… - Cancer Research, 2003 - AACR
The purpose of this research was to quantitate and confirm the mechanism of in vivo metabolic
activation of temozolomide. The secondary aims were to evaluate the tumor, normal tissue…
activation of temozolomide. The secondary aims were to evaluate the tumor, normal tissue…
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study
SR Meikle, JC Matthews, CS Brock, P Wells… - Cancer chemotherapy …, 1998 - Springer
Purpose: The aim of this study was to investigate the feasibility of evaluating the pharmacokinetics
of radiolabeled anti-cancer drugs using spectral analysis, a non-compartmental tracer …
of radiolabeled anti-cancer drugs using spectral analysis, a non-compartmental tracer …
Antitumor Imidazotetrazines. 40. Radiosyntheses of [4-11C-Carbonyl]- and [3-N-11C-Methyl]-8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one …
GD Brown, SK Luthra, CS Brock… - Journal of medicinal …, 2002 - ACS Publications
8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide, 1) is an
anticancer prodrug. As part of investigations to probe its postulated mode of action using PET …
anticancer prodrug. As part of investigations to probe its postulated mode of action using PET …
Glucose metabolism in brain tumours can be estimated using [18F] 2-fluorodeoxyglucose positron emission tomography and a population-derived input function …
CS Brock, H Young, S Osman… - International …, 2005 - spandidos-publications.com
The aim of this study was to assess simplified methods for deriving input functions for estimating
glucose metabolism using 18F-FDG-PET. Nine glioma patients underwent paired 18F-…
glucose metabolism using 18F-FDG-PET. Nine glioma patients underwent paired 18F-…
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast
…, A Lim, S Eccles, M Nathan, CS Brock… - Journal of cutaneous …, 2007 - Wiley Online Library
We report the case of a 38‐year‐old man with metastatic ductal eccrine adenocarcinoma (DEA)
of the left breast responding to 5‐flourouracil, epirubicin and cyclophosphamide (FEC) …
of the left breast responding to 5‐flourouracil, epirubicin and cyclophosphamide (FEC) …
Emerging targeted treatments for malignant glioma
PJ Mulholland, C Thirlwell, CS Brock… - Expert opinion on …, 2005 - Taylor & Francis
This paper focuses on the medical management of malignant gliomas, which is currently
undergoing change. It suggests that as surgery and radiotherapy are of limited benefit in the …
undergoing change. It suggests that as surgery and radiotherapy are of limited benefit in the …
Emergencies in oncology
C Thirlwell, CS Brock - Clinical medicine, 2003 - ncbi.nlm.nih.gov
Tumour lysis syndrome (TLS) comprises several metabolic derangements including:
hyperuricaemia hyperkalaemia hyperphosphataemia secondary hypocalcaemia. These …
hyperuricaemia hyperkalaemia hyperphosphataemia secondary hypocalcaemia. These …
[HTML][HTML] Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [18 F] fluciclatide kinetics and …
Background [ 18 F]fluciclatide, a peptide ligand with high affinity for αvβ3/αvβ5 integrins, is a
proposed biomarker of tumor angiogenesis. The study rationale was to perform a …
proposed biomarker of tumor angiogenesis. The study rationale was to perform a …